Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2023
Updates to the HTA Review Research and Analysis papers collection: draft HTA expert paper published
22 November 2023 - The draft paper 'Optimising the availability and use of real world data and real world evidence to ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 17 Sep 2020
Real world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward
15 September 2020 - There is growing interest globally in using real world data and real-world evidence for health technology assessment. ...
Posted by Michael Wonder on 27 Jul 2019
Australian study evaluates real world evidence of Botox to prevent migraine
26 July 2019 - OnabotulinumtoxinA has been approved by Australia’s reimbursement mechanism for medicines, the PBS, for preventive treatment of ...
Posted by Michael Wonder on 16 Jun 2019
How to deal with the inevitable: generating real-world data and using real-world evidence for HTA purposes – from theory to action
14 June 2019 - Real-world evidence, derived from real-world data, is already used, to some extent, for health technology assessment purposes. ...
Posted by Michael Wonder on 03 Jul 2018
PBAC rejects first submission supported by real-world evidence
4 July 2018 - A retrospective chart review of 211 Australian patients with chronic migraine served as the key evidentiary basis ...
Posted by Michael Wonder on 19 Feb 2018
A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma
13 February 2018 - Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the ...
Posted by Michael Wonder on 19 Sep 2016
Real-world evidence: a comparison of the Australian Herceptin Program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer
19 September 2016 - Estimating the real-world cost-effectiveness of a new drug relies on understanding the differences between clinical trial data ...